ORGO logo

ORGANOGENESIS HOLDINGS INC

ORGONASDAQ
πŸ† #3858 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track ORGO
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$100M
Small Cap
πŸ“ˆRevenue Growth (YoY)
16.8%
Healthy
πŸ“ŠGross Margin
62.0%
High
πŸ’΅FCF Margin
-0.0%
Thin
βš–οΈP/S Ratio
0.3x
Cheap
Otter Score
84
Strong
No chart data available for ORGO.

Trading Snapshot

Day Range
β€”
52-Week Range
$0.73 – $5.91
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
129.8M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$563M
Last Q Revenue
$45M
P/E Ratio
-0.7
P/S Ratio
0.3x
EPS (TTM)
$-1.10
Dividend Yield
0.00%
Dilution (1yr)
+0.0%
ORGO logo

ORGANOGENESIS HOLDINGS INC

ORGO
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$563Mβ–² +16.8% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
75.6%β–Ό βˆ’0.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$56Mβ–Ό βˆ’4454.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$24Mβ–Ό βˆ’685.7% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
132.2Mβ–² +0.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$39Mβ–Ό βˆ’$131M YoY
StockOtter Β· stockotter.space

About ORGANOGENESIS HOLDINGS INC

Organogenesis Holdings Inc. is a U.S.-based regenerative medicine firm that specializes in creating, producing, and marketing innovative therapies for advanced wound management, as well as surgical and sports medicine applications. Within its advanced wound care portfolio, Organogenesis offers several distinct products. These include Affinity and Novachor, both amniotic membrane dressings designed to preserve vital cells, growth factors, and ECM proteins found in natural tissue. Apligraf is a bioengineered living cell therapy that releases a range of healing cytokines and growth factors, while Dermagraft is another bioengineered solution that generates human collagen, ECM, proteins, and cytokines. NuShield provides a wound covering incorporating both amnion and chorion membranes to maintain a spongy intermediate layer. PuraPly acts as an antimicrobial barrier, allowing for flexibility and effective fluid drainage. For the surgical and sports medicine sectors, the company provides products such as NuCel, a dehydrated placental tissue designed for surgical application to promote natural tissue regeneration. ReNu is a cryopreserved suspension aimed at aiding soft tissue recovery. Additionally, FiberOS and OCMP serve as bone void fillers, primarily utilized in orthopedic and neurosurgical procedures. Looking ahead, Organogenesis's product pipeline features PuraPly XT and PuraPly MZ, which are being developed for treating chronic, acute, and open wounds. PuraForce is a bioengineered porcine collagen surgical matrix intended for soft tissue reinforcement. TransCyte, another bioengineered tissue, is in development for addressing partial thickness burns. Organogenesis distributes its offerings to a diverse client base, including hospitals, specialized wound care centers, government institutions, ambulatory surgical centers, and physician offices, leveraging both its direct sales team and independent agencies. Established in 1985, the company maintains its headquarters in Canton, Massachusetts.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
84/100
Analyst data unavailable.

Latest News & Updates

News unavailable.